drugset
drugset / Trial / NCT05823974

A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

NCT05823974 ↗

Phase 1/2 Completed 1275 enrolled GlaxoSmithKline CureVac · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to find and confirm the dose and asses the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine (GSK4382276A) candidates administered in healthy younger and older adults (OA).

Timeline

Start
2023-04-27
Primary completion
2024-07-02
Completion
2024-12-18

Drugs

EvaluationDrugModalityDoseRoute
Subject F2B22A/DL001Z Messenger RNA (mRNA) — Intramuscular
Subject F2B22B/DL001Z Messenger RNA (mRNA) — Intramuscular
Subject F2B22C/DL001Z Messenger RNA (mRNA) — Intramuscular
Subject F2B22D/DL001Z Messenger RNA (mRNA) — Intramuscular
Subject F2B22E/DL001Z Messenger RNA (mRNA) — Intramuscular
Subject F2C22C/DL001Z Messenger RNA (mRNA) — Intramuscular
Subject F2F22A/DL001Z Messenger RNA (mRNA) — Intramuscular
Subject F2F22B/DL001Z Messenger RNA (mRNA) — Intramuscular
Subject F2F22C/DL001Z Messenger RNA (mRNA) — Intramuscular
Subject F2F22D/DL001Z Messenger RNA (mRNA) — Intramuscular
Subject F2F22E/DL001Z Messenger RNA (mRNA) — Intramuscular
Subject F2F22F/DL001Z Messenger RNA (mRNA) — Intramuscular
Subject F2F23A/DL001Z-NH Messenger RNA (mRNA) — Intramuscular
Subject F2F23B/DL001Z-NH Messenger RNA (mRNA) — Intramuscular
Subject F2F23C/DL001Z-NH Messenger RNA (mRNA) — Intramuscular
Subject F2F23D/DL001Z-NH Messenger RNA (mRNA) — Intramuscular

Indications

influenza